Protein Summary
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This locus represents readthrough transcription between the neighboring CYP3A7 (cytochrome P450, family 3, subfamily A, polypeptide 7) and CYP3A51P (cytochrome P450, family 3, subfamily A, polypeptide 51, pseudogene) genes, which are members of the CYP3A gene cluster on chromosome 7. The downstream pseudogene is not known to be independently transcribed. The readthrough transcript includes CYP3A7 exons 1-13 and exons 2 and 13 of the pseudogene. It encodes a CYP3A isoform with a novel C-terminus. This isoform is only expressed in alleles containing a T nucleotide at the -6 position of a splice acceptor in the pseudogene, which enables correct splicing of the upstream CYP3A7 exons to the pseudogene exons. It should be noted th ...more
- ENST00000336374
- ENSP00000337450
- ENSG00000160870
- CYP3A7
- CYPIIIA7
- CYP3A7.1L
- CYP3A7-3AP1
- CYP3A7-CYP3AP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug | 1 | ||
tissue sample | 0.83 | ||
kinase perturbation | 0.81 | ||
PubMedID | 0.76 | ||
gene perturbation | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.79 (req: < 5)
Gene RIFs: 0 (req: <= 3)
Antibodies: 216 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.79 (req: >= 5)
Gene RIFs: 0 (req: > 3)
Antibodies: 216 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1
Expression Data (0 Tissues)
Protein Sequence and Structure
Residue Counts
Protein Sequence
ProtVista Viewer
Related Tools (4)
TIGA scores and ranks GWAS discovered associations according to the quantity and quality of the evidence supporting the association.
GENEVA (GENe Expression Variance Analysis) allows you to identify RNA-sequencing datasets from the Gene Expression Omnibus (GEO) that contain conditions modulating a gene or a gene signature.
GlyGen is a data integration and dissemination project for carbohydrate and glycoconjugate related data.
ARCHS4 provides access to gene-function predictions based on RNA-seq co-expression, and gene expression levels across cell and tissues.
Approved Drugs (1)
Active Ligands (0)
Protein-Protein Interactions (75)
CYP3A4
Family: Enzyme
Novelty: 0.00015515
p_int: 0.999999995
p_wrong: 5e-9
Score: 0.957
Data Source: BioPlex,STRINGDB
CYP3A5
Family: Enzyme
Novelty: 0.00105607
p_int: 0.999999926
p_wrong: 7.5e-8
Score: 0.969
Data Source: BioPlex,STRINGDB
CYSTM1
Novelty: 1.37759108
p_int: 0.800914751
p_ni: 0.002910154
p_wrong: 0.196175096
Data Source: BioPlex
Nearest Tclin Targets
Pathways (10)
Reactome (5)
KEGG (4)
PathwayCommons (1)
Click on a row in the table to change the structure displayed.
Data Source | Name | Explore in Pharos | Explore in Source | ||
|---|---|---|---|---|---|
Reactome | Biological oxidations | ||||
Reactome | Cytochrome P450 - arranged by substrate type | ||||
Reactome | Metabolism | ||||
Reactome | Phase I - Functionalization of compounds | ||||
Reactome | Xenobiotics | ||||
Name | Explore in Pharos | Explore in Source | ||
|---|---|---|---|---|
Biological oxidations | ||||
Cytochrome P450 - arranged by substrate type | ||||
Metabolism | ||||
Phase I - Functionalization of compounds | ||||
Xenobiotics | ||||
Viral Interactions (0)
Gene Ontology Terms (12)
Functions (7)
Components (2)
Processes (3)
GO Term | Evidence | Assigned by | ||
|---|---|---|---|---|
Inferred from Direct Assay (IDA) | BHF-UCL | |||
Inferred from Direct Assay (IDA) | BHF-UCL | |||
Inferred from Sequence or structural Similarity (ISS) | UniProtKB | |||
Traceable Author Statement (TAS) | ProtInc | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Inferred from Electronic Annotation (IEA) | InterPro | |||
Inferred from Electronic Annotation (IEA) | InterPro | |||
Disease Associations (null)
GWAS Traits (19)
Items per page:
1 – 5 of 19
GWAS Trait | EFO ID | Study Count | SNP Count | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
|---|---|---|---|---|---|---|---|---|---|
tacrolimus measurement | 2 | 3 | 5 | 99.3 | |||||
serum metabolite measurement | 1 | 2 | 2 | 91.7 | |||||
urinary metabolite measurement | 1 | 2 | 2 | 86.1 | |||||
ticagrelor measurement | 1 | 2 | 2 | 83.6 | |||||
sex hormone-binding globulin measurement | 8 | 2 | 7 | 5.8 | 78.4 | ||||
Items per page:
1 – 5 of 19
GWAS Trait | EFO ID | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
|---|---|---|---|---|---|---|---|
tacrolimus measurement | 5 | 99.3 | |||||
serum metabolite measurement | 2 | 91.7 | |||||
urinary metabolite measurement | 2 | 86.1 | |||||
ticagrelor measurement | 2 | 83.6 | |||||
sex hormone-binding globulin measurement | 7 | 5.8 | 78.4 | ||||
Find similar targets by:
IDG Resources
Orthologs
Publication Statistics
PubMed Score 141.79
PubMed score by year
PubTator Score 0.33
PubTator score by year
Related Publications
Text Mined References (5)
Items per page:
0 of 0
PMID | Year | Title |
|---|